| Authors: |
Wong K; Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK., Masoud S; Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK., Pitcher D; Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK., Downward L; National Registry of Rare Kidney Diseases, Bristol, UK., Proudfoot C; Health Economics and Outcomes Research (HEOR), Novartis Pharma AG, Basel, Switzerland., Webb NJA; Health Economics and Outcomes Research (HEOR), Novartis Pharma AG, Basel, Switzerland., Wong EKS; National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Gale DP; Centre for Kidney and Bladder Health, University College London, UK; National Registry of Rare Kidney Diseases, Bristol, UK. Electronic address: d.gale@ucl.ac.uk. |
